Lundbeck has initiated phase I trial of acquired candidate
The first patients have been recruited and dosed in a phase I study with a potential new treatment for neurological conditions, Lu AG22515, which Lundbeck acquired last October.
by mikkel aabenhus hemmingsen, translated by daniel pedersen
For the first time, a person has been dosed with Lu AG22515, a candidate that Lundbeck acquired for USD 16m upfront payment from South Korean biotech company Aprilbio in October last year, in a deal which also included potential milestone payments of USD 432m.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
